keyword
https://read.qxmd.com/read/38462636/discovery-of-a-novel-small-molecule-as-cd47-sirp%C3%AE-and-pd-1-pd-l1-dual-inhibitor-for-cancer-immunotherapy
#21
JOURNAL ARTICLE
Shengzhe Jin, Hongfei Wang, Yang Li, Jingwen Yang, Beibei Li, Peishang Shi, Xiangrui Zhang, Xiaowen Zhou, Xiuman Zhou, Xiaoshuang Niu, Menghan Wu, Yahong Wu, Wenjie Zhai, Yuanming Qi, Yanfeng Gao, Wenshan Zhao
BACKGROUND: Targeting the tumor microenvironment (TME) has emerged as a promising strategy in cancer treatment, particularly through the utilization of immune checkpoint blockade (ICB) agents such as PD-1/PD-L1 inhibitors. Despite partial success, the presence of tumor-associated macrophages (TAMs) contributes to an immunosuppressive TME that fosters tumor progression, and diminishes the therapeutic efficacy of ICB. Blockade of the CD47/SIRPα pathway has proven to be an effective intervention, that restores macrophage phagocytosis and yields substantial antitumor effects, especially when combined with PD-1/PD-L1 blockade...
March 11, 2024: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/38441961/tgf-%C3%AE-1-induces-pd-1-expression-in-macrophages-through-smad3-stat3-cooperative-signaling-in-chronic-inflammation
#22
JOURNAL ARTICLE
Zhigang Lei, Rui Tang, Yu Wu, Chenxu Mao, Weijie Xue, Junyao Shen, Jiaojiao Yu, Xiaohong Wang, Xin Qi, Chuan Wei, Lei Xu, Jifeng Zhu, Yalin Li, Xiujun Zhang, Chunyan Ye, Xiaojun Chen, Xiaojun Yang, Sha Zhou, Chuan Su
Programmed cell death protein 1 (PD-1), a coinhibitory T-cell checkpoint, is also expressed on macrophages (Mφ) in pathogen- or tumor-driven chronic inflammation. Increasing evidence underscores the importance of PD-1 on Mφ for dampening immune responses. However, the mechanism governing PD-1 expression in Mφ in chronic inflammation remains largely unknown. TGF-β1 (transforming growth factor-β1) is abundant within chronic inflammatory microenvironments. Here, based on public databases, significant positive correlations between PDCD1 and TGFB1 gene expression were observed in most human tumors...
March 5, 2024: JCI Insight
https://read.qxmd.com/read/38439072/n-6-methyladenosine-levels-in-peripheral-blood-rna-a-potential-diagnostic-biomarker-for-colorectal-cancer
#23
JOURNAL ARTICLE
Yingping Cao, Chunying Zhang, Jiadi Chen, Jingyi Ren, Xiaoyu Li, Yaqin Zhang, Bihan Huang, Yihan Xu, Luyan Dong
BACKGROUND: N6 -methyladenosine (m6 A) is dysregulated in various cancers, including colorectal cancer (CRC). Herein, we assess the diagnostic potential of peripheral blood (PB) m6 A levels in CRC. METHODS: We collected PB from healthy controls (HCs) and patients with CRC, analyzed PB RNA m6 A levels and the expression of m6 A-related demethylase genes FTO and ALKBH5, cocultured CRC cells with PB mononuclear cells (PBMCs), and constructed an MC38 cancer model. RESULTS: PB RNA m6 A levels were higher in the CRC than that in HCs...
March 5, 2024: Cancer Cell International
https://read.qxmd.com/read/38428724/improved-antitumor-effects-elicited-by-an-oncolytic-hsv-1-expressing-a-novel-b7h3nb-cd3-bsab
#24
JOURNAL ARTICLE
Zongliang Zhang, Nian Yang, Huaqing Lu, Yongdong Chen, Long Xu, Zeng Wang, Qizhong Lu, Kunhong Zhong, Zhixiong Zhu, Guoqing Wang, Hexian Li, Meijun Zheng, Weiwei Zhang, Hui Yang, Xingchen Peng, Liangxue Zhou, Aiping Tong
Oncolytic viruses have emerged as a promising modality for cancer treatment due to their unique abilities to directly destroy tumor cells and modulate the tumor microenvironment. Bispecific T-cell engagers (BsAbs) have been developed to activate and redirect cytotoxic T lymphocytes, enhancing the antitumor response. To take advantage of the specific infection capacity and carrying ability of exogenous genes, we generated a recombinant herpes simplex virus type 1 (HSV-1), HSV-1dko -B7H3nb/CD3 or HSV-1dko -B7H3nb/mCD3, carrying a B7H3nb/CD3 or B7H3nb/mCD3 BsAb that replicates and expresses BsAb in tumor cells in vitro and in vivo...
February 28, 2024: Cancer Letters
https://read.qxmd.com/read/38427670/generation-of-murine-tumor-models-refractory-to-%C3%AE-pd-1-l1-therapies-due-to-defects-in-antigen-processing-presentation-or-ifn%C3%AE-signaling-using-crispr-cas9
#25
JOURNAL ARTICLE
Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Immune checkpoint blockade (ICB) targeting the programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) fails to provide clinical benefit for most cancer patients due to primary or acquired resistance. Drivers of ICB resistance include tumor antigen processing/presentation machinery (APM) and IFNγ signaling mutations. Thus, there is an unmet clinical need to develop alternative therapies for these patients. To this end, we have developed a CRISPR/Cas9 approach to generate murine tumor models refractory to PD-1/-L1 inhibition due to APM/IFNγ signaling mutations...
2024: PloS One
https://read.qxmd.com/read/38426110/combined-effects-of-exercise-and-immuno-chemotherapy-treatments-on-tumor-growth-in-mc38-colorectal-cancer-bearing-mice
#26
JOURNAL ARTICLE
Manon Gouez, Amélie Rébillard, Amandine Thomas, Sabine Beaumel, Eva-Laure Matera, Etienne Gouraud, Luz Orfila, Brice Martin, Olivia Pérol, Cédric Chaveroux, Erica N Chirico, Charles Dumontet, Béatrice Fervers, Vincent Pialoux
Acute exercise induces transient modifications in the tumor microenvironment and has been linked to reduced tumor growth along with increased infiltration of immune cells within the tumor in mouse models. In this study, we aimed to evaluate the impact of acute exercise before treatment administration on tumor growth in a mice model of MC38 colorectal cancer receiving an immune checkpoint inhibitor (ICI) and chemotherapy. Six-week-old mice injected with colorectal cancer cells (MC38) were randomized in 4 groups: control (CTRL), immuno-chemotherapy (TRT), exercise (EXE) and combined intervention (TRT/EXE)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38423673/pre-and-post-high-intensity-interval-training-delays-colon-tumor-onset-in-a-syngeneic-mouse-model
#27
JOURNAL ARTICLE
Eduardo Figueiredo Silva, Bruno Nappo Fernandes, Poliana Marinello, Rafael Deminice, Julio Cesar Freitas Junior, Sheila Coelho Soares-Lima, Fernando Tadeu Trevisan Frajacomo, Luis Felipe Ribeiro Pinto
BACKGROUND/AIM: High-intensity interval training (HIIT) can trigger transient anti-tumor cytotoxicity through the mobilization of natural killer cells (NK cells) and myokines. Yet, the effects of HIIT on tumor development and microenvironment are unclear. MATERIALS AND METHODS: Male C57/BL6 mice were administered either MC38 of syngeneic colon cancer cells or vehicle in a single subcutaneous injection. Before injection, the training group completed four weeks of the HIIT program (progressive swimming training, 3/week, 10-12 min, 4-6% of body weight for overload)...
March 2024: Anticancer Research
https://read.qxmd.com/read/38414530/lgr5-as-a-therapeutic-target-of-antibody-functionalized-biomimetic-magnetoliposomes-for-colon-cancer-therapy
#28
JOURNAL ARTICLE
Ana Cepero, Mónica Jiménez-Carretero, Ylenia Jabalera, Lidia Gago, Cristina Luque, Laura Cabeza, Consolación Melguizo, Concepcion Jimenez-Lopez, José Prados
PURPOSE: The lack of specificity of conventional chemotherapy is one of the main difficulties to be solved in cancer therapy. Biomimetic magnetoliposomes are successful chemotherapy controlled-release systems, hyperthermia, and active targeting agents by functionalization of their surface with monoclonal antibodies. The membrane receptor Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) stands out as colorectal cancer (CRC) biomarker and appears to be related to treatment resistance and the development of metastasis...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38400885/intestinal-microbiota-modulates-the-antitumor-effect-of-oncolytic-virus-vaccines-in-colorectal-cancer
#29
JOURNAL ARTICLE
Xia Chen, Guanjun Wang, Ling Qin, Bing Hu, Jun Li
BACKGROUND: Immunotherapies, such as oncolytic viruses, have become powerful cancer treatments, but only some patients with cancer can benefit from them, especially those with advanced-stage cancer, and new therapeutic strategies are needed to facilitate extended survival. The intestinal microbiota may contribute to colorectal cancer (CRC) carcinogenesis and the response to immunotherapy. However, whether and how the intestinal microbiota modulates the effects of oncolytic virus vaccines (OVVs) in CRC remain to be investigated...
February 24, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38379869/a-bispecific-anti-pd-1-and-pd-l1-antibody-induces-pd-1-cleavage-and-provides-enhanced-anti-tumor-activity
#30
JOURNAL ARTICLE
Diana I Albu, Benjamin J Wolf, Yan Qin, Xianzhe Wang, Amy Daniel Ulumben, Mei Su, Vivian Li, Eirene Ding, Jose Angel Gonzalo, Jason Kong, Ruturaj Jadhav, Nelly Kuklin, Alberto Visintin, Bing Gong, Thomas J Schuetz
Combinatorial strategies, such as targeting different immune checkpoint receptors, hold promise to increase the breadth and duration of the response to cancer therapy. Here we describe the preclinical evaluation of CTX-8371, a protein construct which combines PD-1 and PD-L1 targeting in one bispecific, tetravalent antibody. CTX-8371 matched or surpassed the activity of anti-PD-1 and PD-L1 benchmark antibodies in several in vitro T cell activation assays and outperformed clinically approved benchmarks in the subcutaneous MC38 colon and the B16F10 lung metastasis mouse tumor models...
2024: Oncoimmunology
https://read.qxmd.com/read/38369833/-construction-and-identification-of-a-stable-ct26-cell-line-expressing-cd19-fluc-gfp
#31
JOURNAL ARTICLE
Yujie Guo, Haixiao Duan, Yining Cheng, Binfeng Yang, Han Hu, Binlei Liu, Yang Wang
Solid tumors lack well-defined targets for chimeric antigen receptor T-cell (CAR-T) therapy. Therefore, introducing a known target molecule, CD19, into solid tumor cell lines via lentiviral transduction to investigate the cytotoxicity of CD19 CAR-T cells can potentially support CAR-T cell therapy against solid tumors. In this study, a stable colon cancer CT26 cell line, CT26-CD19-FLUC-GFP, expressing CD19, firefly luciferase (FLUC), and green fluorescent protein (GFP), was constructed using a triple-plasmid lentiviral system...
February 25, 2024: Sheng Wu Gong Cheng Xue Bao, Chinese Journal of Biotechnology
https://read.qxmd.com/read/38351129/cold-atmospheric-plasma-stabilizes-mismatch-repair-for-effective-uniform-treatment-of-diverse-colorectal-cancer-cell-types
#32
JOURNAL ARTICLE
Yuanyuan He, Fu Lu, Chenmin Jiang, Fanwu Gong, Zhengwei Wu, Kostya Ostrikov
Mismatch Repair (MMR) mechanisms play a pivotal role in rectifying DNA replication errors and maintaining the stability of DNA microsatellite structure. Colorectal cancer (CRC) can be characterized into microsatellite stability (MSS) and microsatellite instability (MSI) subtypes based on the functionality of MMR. MSI CRC notably exhibits enhanced chemotherapy resistance, attributable to diminished MMR-related protein expression. Cold atmospheric plasma (CAP) has emerged as a promising treatment modality, demonstrating efficacy in inducing apoptosis in various cancer cells...
February 13, 2024: Scientific Reports
https://read.qxmd.com/read/38315285/targeting-mek-cox-2-axis-improve-immunotherapy-efficacy-in-dmmr-colorectal-cancer-with-pik3ca-overexpression
#33
JOURNAL ARTICLE
Kunwei Peng, Yongxiang Liu, Shousheng Liu, Zining Wang, Huanling Zhang, Wenzhuo He, Yanan Jin, Lei Wang, Xiaojun Xia, Liangping Xia
PURPOSE: PIK3CA mutation or overexpression is associated with immunotherapy resistance in multiple cancer types, but is also paradoxically associated with benefit of COX-2 inhibition on patient survival of colorectal cancer (CRC) with mismatch repair deficiency (dMMR). This study examined whether and how PIK3CA status affected COX-2-mediated tumor inflammation and immunotherapy response of dMMR CRC. METHODS: Murine colon cancer cells MC38, CT26, and CT26-Mlh1-KO were used to construct PIK3CA knockdown and overexpression models to mimic dMMR CRC with PIK3CA dysregulation, and xenograft models were used to evaluate how PIK3CA regulate COX-2 expression, CD8+ T cells infiltration, tumor growth, and therapy response to anti-PD-L1 treatment using immunocompetent mice...
February 5, 2024: Cellular Oncology (Dordrecht)
https://read.qxmd.com/read/38310462/ir-780-dye-based-targeting-of-cancer-associated-fibroblasts-improves-cancer-immunotherapy-by-increasing-intra-tumoral-t-lymphocytes-infiltration
#34
JOURNAL ARTICLE
Wei Yang, Zelin Chen, Langfan Qu, Can Zhang, Hongdan Chen, Jiancheng Zheng, Wanchao Chen, Xu Tan, Chunmeng Shi
BACKGROUND: Immune-checkpoint inhibitors (ICIs) against programmed death (PD)-1/PD-L1 pathway immunotherapy have been demonstrated to be effective in only a subset of patients with cancer, while the rest may exhibit low response or may develop drug resistance after initially responding. Previous studies have indicated that extensive collagen-rich stroma secreted by cancer-associated fibroblasts (CAFs) within the tumor microenvironment is one of the key obstructions of the immunotherapy for some tumors by decreasing the infiltrating cytotoxic T cells...
January 5, 2024: Current Cancer Drug Targets
https://read.qxmd.com/read/38309054/camptothesome-based-combination-nanotherapeutic-regimen-for-improved-colorectal-cancer-immunochemotherapy
#35
JOURNAL ARTICLE
Zhiren Wang, Wenpan Li, Yanhao Jiang, Tuyen Ba Tran, Jinha Chung, Minhyeok Kim, Aaron James Scott, Jianqin Lu
Camptothesome is a sphingomyelin-conjugated camptothecin (SM-CSS-CPT) nanovesicle that fortified the therapeutic delivery of CPT in diverse cancer types. To mitigate the Camptothesome-induced IDO1 negative feedback mechanism, we had co-encapsulated, indoximod (IND, IDO1 inhibitor) into Camptothesome using doxorubicin-derived IND (DOX-IND). To maximize the therapeutic potential of DOX-IND/Camptothesome, herein, we first dissected the synergistic drug ratio (DOX-IND/SM-CSS-CPT) via systematical in vitro screening...
January 18, 2024: Biomaterials
https://read.qxmd.com/read/38293128/mait-cells-modulate-innate-immune-cells-and-inhibit-colon-cancer-growth
#36
Olivia J Cheng, Eric J Lebish, Owen Jensen, Damian Jacenik, Shubhanshi Trivedi, Jackson Cacioppo, Jeffrey Aubé, Ellen J Beswick, Daniel T Leung
UNLABELLED: Mucosal-associated invariant T (MAIT) cells are innate-like T cells that can be activated by microbial antigens and cytokines and are abundant in mucosal tissues including the colon. MAIT cells have cytotoxic and pro-inflammatory functions. Despite their potential for adoptive cell therapy, studies into their anti-cancer activity, including their role in colon cancer, are limited. We expanded MAIT cells in vivo and injected them into RAG1 -/- mice with MC38-derived tumors and tumor growth was assessed...
January 19, 2024: bioRxiv
https://read.qxmd.com/read/38291470/pitpnc1-suppress-cd8-t-cell-immune-function-and-promote-radioresistance-in-rectal-cancer-by-modulating-fasn-cd155
#37
JOURNAL ARTICLE
Junxian Liang, Limin Liao, Lang Xie, WenWen Tang, Xiang Yu, Yinghao Lu, Hongzhen Chen, Juanli Xu, Lei Sun, Huanmei Wu, Chunhui Cui, Yujing Tan
BACKGROUND: Radioresistance is a primary factor contributing to the failure of rectal cancer treatment. Immune suppression plays a significant role in the development of radioresistance. We have investigated the potential role of phosphatidylinositol transfer protein cytoplasmic 1 (PITPNC1) in regulating immune suppression associated with radioresistance. METHODS: To elucidate the mechanisms by which PITPNC1 influences radioresistance, we established HT29, SW480, and MC38 radioresistant cell lines...
January 30, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38286241/dna-dependent-protein-kinase-regulates-cytosolic-double-stranded-dna-secretion-from-irradiated-macrophages-to-increase-radiosensitivity-of-tumors
#38
JOURNAL ARTICLE
Taerim Oh, Gi-Sue Kang, Hye-Ju Jo, Hye-Joon Park, Ye-Rim Lee, G-One Ahn
BACKGROUND AND PURPOSE: To investigate the molecular mechanism by which irradiated macrophages secrete cytosolic double-stranded DNA (c-dsDNA) to increase radiosensitivity of tumors. MATERIALS AND METHODS: Irradiated bone marrow-derived macrophages (BMDM) were co-incubated with irradiated EO771 or MC38 cancer cells to determine clonogenic survival. c-dsDNA were measured by agarose gel or enzyme-linked immunosorbent assay. BMDM or cancer cells were analyzed with immunostaining or western blot...
January 27, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38278025/astragalus-polysaccharide-ameliorates-cd8-t-cell-dysfunction-through-stat3-gal-3-lag3-pathway-in-inflammation-induced-colorectal-cancer
#39
JOURNAL ARTICLE
Qiuyi Li, Chonghao Zhang, Guichuan Xu, Xuekai Shang, Xinmei Nan, Yalan Li, Jiajing Liu, Yanfei Hong, Qing Wang, Guiying Peng
Chronic inflammation can promote cancer development as observed in inflammation-induced colorectal cancer (CRC). However, the poor treatment outcomes emphasize the need for effective treatment. Astragalus polysaccharide (APS), a vital component of the natural drug Astragalus, has anti-tumor effects by inhibiting cancer cell proliferation and enhancing immune function. In this study, we found that APS effectively suppressed CRC development through activating CD8+ T cells and reversing its inhibitory state in the tumor microenvironment (TME) of AOM/DSS inflammation-induced CRC mice...
January 24, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38272565/lrp11-promotes-stem-like-t-cells-via-mapk13-mediated-tcf1-phosphorylation-enhancing-anti-pd1-immunotherapy
#40
JOURNAL ARTICLE
Lingjuan Sun, Zhibo Ma, Xiangli Zhao, Xiaosheng Tan, Yuhao Tu, Jingzeng Wang, Li Chen, Zhishui Chen, Gang Chen, Peixiang Lan
BACKGROUND: Tumor-infiltrating T cells enter an exhausted or dysfunctional state, which limits antitumor immunity. Among exhausted T cells, a subset of cells with features of progenitor or stem-like cells has been identified as TCF1+ CD8+ T cells that respond to immunotherapy. In contrast to the finding that TCF1 controls epigenetic and transcriptional reprogramming in tumor-infiltrating stem-like T cells, little is known about the regulation of TCF1. Emerging data show that elevated body mass index is associated with outcomes of immunotherapy...
January 25, 2024: Journal for Immunotherapy of Cancer
keyword
keyword
168000
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.